Login to Your Account



Gilead's Earnings Take a Dive as AIDS Drug Sales Soften

By Catherine Shaffer


Friday, April 22, 2011
Weak sales of its HIV drugs in the U.S. pushed Gilead Sciences Inc.'s earnings down in the first quarter. Revenues of $1.93 billion were below consensus estimates and down 8 percent from the first quarter of 2010.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription